Autoimmune/Paraneoplastic Epilepsy
Evaluation Algorithm - Spinal Fluid

The following tests are always performed:

- Glutamic acid decarboxylase (GAD65) antibody assay
- Antineuronal nuclear antibody-type 1 (ANNA-1)
- Antineuronal nuclear antibody-type 2 (ANNA-2)
- Antineuronal nuclear antibody-type 3 (ANNA-3)
- Purkinje cell cytoplasmic antibody, type 2 (PCA-2)
- Purkinje cell cytoplasmic antibody, type 3 (PCA-3)
- Amphiphysin antibody assay
- Collapsin response-mediator protein-5 neuronal (CRMP-5-IgG)
- Anti-glia/neuronal nuclear antibody-type 1 (AGNA-1)
- Dippeptidyl-peptidase-like protein-6 (DPPX) antibody
- Metabotropic glutamate receptor 1 (mGluR1) antibody
- Glial fibrillary acidic protein (GFAP) alpha subunit antibody

If IFA pattern suggests ANNA-2:
- If IFA pattern suggests CRMP-5 IgG:
  - ANNA-1 antibody by immunoblot
  - CRMP-5-IgG Western blot
  - DPPX antibody by CBA
  - DPPX antibody by immunofluorescence (IF) titer assay

If IFA pattern suggests PCA-1:
- If IFA pattern suggests AMPA-receptor antibody and AMPA-receptor antibody, CBA are positive:
  - AMPA-receptor antibody IF titer assay
  - PCA-1 antibody by immunoblot
  - GABA-B-receptor antibody IF titer assay
  - GABA-B-receptor antibody by immunoblot

If IFA pattern suggests AMPA-receptor antibody and AMPA-receptor antibody, CBA are positive:
- If IFA pattern suggests NMDA-receptor antibody and NMDA-receptor antibody, CBA are positive:
  - NMDA-receptor antibody
  - AMPA-receptor antibody
  - GABA-B-receptor antibody
  - Contactin-associated protein-like-2 (CASPR2)-IgG
  - Leucine-rich glioma inactivated protein-1 (Lgi1) IgG